Skip to main content

Table 1 Characteristics of all eligible studies for lipid profile and risk of ovarian tumours

From: Lipid profile and risk of ovarian tumours: a meta-analysis

Authors

Year

Country

Cases

Control

Lipid profilea

Ascertainment of ovarian tumour cases

Classificationf

Accountability of bias

Bukhari et al. [7]

2016

Pakistan

30

30e

TC, TG, HDL, LDLb

Hospital/Medical record confirmed using color flow Doppler tests, biopsies and MRI

NR

NR

Camuzcuoglu et al. [6]

2009

Turkey

24

29e

TC, TG, HDL, LDLb

Hospital/Medical record

FIGO

Excludedg, h

Chen et al. [16]

2017

China

573

1146d

TG, HDLb

Hospital confirmed

FIGO

Excludedh,i

Das et al. [17]

1987

China

28

66e

TCb

Histopathological examinations

NR

NR

Delimaris et al. [10]

2007

Greece

15

30d

TC, HDL, LDLb

Hospital/Medical records,

TNM

Excludedg

Gadomska et al. [18]

1997

NR

25

25e

TC, TG, HDLb

Histopathological examinations

FIGO

NR

Gadomska et al. [9]

2005

Poland

91

44 e

TC, TG, HDLb

Histopathological examinations, Transvaginal ultrasonography,

FIGO

NR

Knapp et al. [19]

2017

Poland

74

81e

TC, TG

Transvaginal sonography evaluation, Histopathological examinations, CT scan

FIGO

Excludedh,i

Kuesel et al. [20, 23]

1992

Canada

62

51e

TC, TG

NR

FIGO

NR

Melvin et al [8]

2012

Sweden

786

227,603d

TC, TG, HDL, LDLb

Verifiable database

NR

NR

Qadir et al. [21]

2008

Pakistan

40

50d

TC, TG, HDL, LDLb

NR

NR

Excludedh

Yam et al. [22]

1994

Israel

19

12c

TC, TG, HDL, LDLb

Biopsies of ovary/endometrium

NR

NR

  1. NR-not reported; a-lipid profile reported in the study; b-lipid profile assessed in fasting state; c-hospital-based controls; d-population-based controls e-unspecified type of controls; MRI-magnetic resonance imaging; f-method adopted for tumour classification; FIGO-International Federation of Gynecologists and Obstetricians; TNM-The TNM Classification of Malignant Tumours
  2. gPatients with previously-performed chemo-therapy, radiotherapy and surgery
  3. hPatients with concurrent or previous malignant disease or any other disease
  4. iPatients with suspected abnormalities such as neoplastic effects etc